Reading SXTP? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SXTP free→Reading SXTP? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SXTP free→QuarterlyIQ Insights · SXTP
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Other Events The Company intends to submit an application for a Commissioner’s National Priority Review Voucher if the outcome of any interim and/or final analysis of the Company’s randomized, placebo-controlled trial of tafenoquine in patients hospitalized with severe babesiosis supports moving forward with a New Drug Application submission to the U.S. Food and Drug Administration (“FDA”) before the end of the first quarter of 2028. The Company is providing this disclosure to inform investor…
Departure of Directors or Certain Officers: Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 13, 2026, the Board of Directors (the “Board”) of 60 Degrees Pharmaceuticals, Inc. (the “Company”) appointed Eric Francois to serve as a member of the Board, effective immediately. Mr. Francois is a strategic financial executive with over 20 years of leadership experience in the healthcare and life sciences sectors. He currently serves as an…
Other Events. On March 20, 2026, the Company determined that an error was made in the calculation of the number of shares of common stock beneficially owned by an affiliate of the Company, which was disclosed in the Company’s prospectus supplement dated March 13, 2026 (the “Prospectus Supplement”). Specifically, the number of shares beneficially owned by such affiliate was incorrectly reported as 21,490 shares. The correct number of shares beneficially owned by such affiliate is 23,367 shares…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On January 20, 2026, 60 Degrees Pharmaceuticals, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that Nasdaq staff has determined to delist the Company’s common stock and warrants from The Nasdaq Capital Market. As disclosed in the Notice, Nasdaq staff determined that the Company…
of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished pursuant to Regulation FD and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The presentation contains forward-lo…
Entry into a Material Definitive Agreement. On September 3, 2025, 60 Degrees Pharmaceuticals, Inc. (the “Company”) entered into an At-The-Market Sales Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”) pursuant to which the Company may, from time to time, offer and sell shares (the “ATM Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”), having aggregate gross sales proceeds of up to $1,397,533 (the “ATM Offering”), through or to Wainw…
Termination of a Material Definitive Agreement. On September 3, 2025, 60 Degrees Pharmaceuticals, Inc. (the “Company”) and Wallachbeth Capital LLC (“Wallachbeth”) entered into a Waiver and Termination Agreement of the At-The-Market Issuance Sales Agreement, dated June 4, 2024 (the “ATM Agreement”). The Company and Wallachbeth agreed to waive the 10-day notice termination period (the “Notice Termination Period”), and the Company exercised its right to the immediate termination of the ATM Agree…
Entry into a Material Definitive Agreement. On July 15, 2025, 60 Degrees Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Investors”) relating to the sale of (i) 1,753,314 share of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), (ii) 878,264 pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 878,264 shares of Common Stock, (iii) Series A-1 warran…
Entry into a Material Definitive Agreement. On January 28, 2025, 60 Degrees Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors (the “Purchasers”) pursuant to which the Company sold, in a registered direct offering an aggregate of 1,021,549 shares (the “Shares”) of common stock, par value $0.0001 per share, of the Company (“Common Stock”) at a purchase price of $1…
Unregistered Sales of Equity Securities. The disclosures set forth in
Importance-ranked changes since the prior daily snapshot.
Valuation label changed from 'inexpensive' to 'None'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.